Wall Street Advisors
Wall Street Playbook, Wall Street Playbook (120 clicks)
Long only, deep value, value, long-term horizon
Profile| Send Message| Follow (49)
Why Apple And Amazon Are No Threat To Netflix, Stock Will Regain $400
Apr. 17, 2014 2:49 PM ET | About: NFLX, Includes: AAPL, AMZN, CMCSA
Disclosure: I am long AAPL. (More...)
On the basis of growing free cash flow, revenue and global subscribers, these shares will regain their $400 market shortly after these results are announced.
Netflix has amassed 44 million worldwide subscribers and expect to grow that figure by an additional 4 million in 2014, helped by Netflix's ability to differentiate itself.
Given Apple's strict attention to profit margins, Apple is not likely to follow Netflix's unlimited streaming model.
Netflix (NFLX) is set to report its first-quarter earnings results on Monday. With all of the talks about a possible acquisition by Apple (AAPL) and or the fact that Apple has become a competitor, investors have already forgotten that Netflix still has a dominant business, one that has consistently demolished both earnings and guidance.
Netflix: A Strong Buy on the Pullback
By Ishfaque Faruk | More Articles
April 2, 2014
The stock price of Netflix (NASDAQ: NFLX ) has dropped from its high in the $450s to its current levels.There has been speculation about Apple (NASDAQ: AAPL ) and Comcast (NASDAQ: CMCSA ) trying to work together to structure an Internet-to-TV streaming deal. This sizable drop in stock price represents a great buying opportunity for long-term investors.
Apple-Comcast deal will have no impact
When rumors surfaced about Comcast talking with Apple to deliver TV and on-demand video through the Apple TV set-box, the stock price of Netflix took a big hit. This piece of news, even if it is true, is highly immaterial for Netflix and its shareholders. Comcast will most likely appear as an app on the menu of Apple TV, just like those of Hulu and Netflix. Comcast will certainly only make this deal available to its subscribers, and it will give consumers more options but it provides almost no benefit to someone who does not have an Apple TV device
Clovis Oncology’s CO-1686 Demonstrates Compelling Clinical Activity and Progression-free Survival (PFS) in Updated Phase 1 Study Results in Patients with Non-small Cell Lung Cancer (NSCLC)
64% objective response rate observed in T790M+ patients
PFS greater than six months in heavily-pretreated T790M+ patient population; median not yet reached
March 31, 2014
(TSLA ) $304.00 target price on the stock.Zacks’ analyst wrote, “We are raising Tesla Motors to Outperform based on its rising production and sales and rapid international expansion. The company hasclinched a substantial share of the electric car market, thanks to an impressive product portfolio and a rapidly developing Supercharger network. Less
Gilead's Sovaldi sales through the roof already, analyst predicts at least $8B this year
Hep C product on target to unseat Lipitor as the biggest-selling drug ever By Carly Helfand
With a revolutionary approach to hepatitis C and a price tag of $84,000 per 12-week treatment course, analysts expected big sales from Gilead's ($GILD) Sovaldi. Some even forecast it would reach $9 billion or more by 2017, at which level it would surpass Pfizer's ($PFE) Lipitor to take the crown for biggest-selling drug of all time. But none expected the exponential growth the drug is posting right now.
New Sovaldi prescriptions were up 20% week-over-week for the week ended Feb. 28--the 12th week of Gilead's launch. And according to ISI Group analyst Mark Schoenebaum, that has current projections looking rather slim.
"If prescriptions were to NEVER GROW AGAIN (i.e. flat-line from here), I estimate that 2014 sales will be $8B. If scrips grow an average of 1.5% week over week, I estimate that 2014 sales will be about $11B.
And as RBC analyst Michael Yee notes, Sovaldi's weekly total prescriptions are tracking 114% higher thanwhat Incivek--a Vertex ($VRTX) hep C drug that holds the title for fastest drug launch ever after raking in $1.56 billion in four quarters--did in its first full quarter of launch.
The Fly On the Wall
March 26, 2014
10:06 EDT CLVS Clovis advances ahead of clinical trial update
Shares of Clovis (CLVS) are rising a day before the company is slated to report interim results from a study of its CO-1686 drug. CO-1686 is supposed to treat non-small cell lung cancer. WHAT'S NOTABLE: In a regulatory filing on February 27, Clovis said that it would provide an update on clinical results from a Phase I study of CO-1686. The update will include results from patients treated with the hydrobromide salt formulation that will be used in all clinical studies going forward, the company stated. The results are slated to be presented during a session that will be held between 10 am ET and 11:30 am ET, Clovis reported. CO-1686 is supposed to mutant forms of the epidermal growth factor receptor and the T790M resistance mutation. ANALYST REACTION: In a note to investors earlier today, Leerink Swann analyst Mark Kozul estimated that there is about an 85% chance that the stock will rise following tomorrow's update. The stock could jump more than $15-$20 if the data lowers CO-1686's risk, he predicted.
bought and loaded up
Google to Verify
Telsa Motors ( TSLA )
Tesla Motors Upgraded to “Outperform” at Zacks (TSLA)
Zacks upgraded shares of Tesla Motors (NASDAQ:TSLA) from a neutral rating to an outperform rating in a report issued on Thursday, Stock Ratings News reports. They currently have $304.00 target price on the stock.Zacks’ analyst wrote, “We are raising Tesla Motors to Outperform based on its rising production andsales and rapid international expansion. The company has clinched a substantial share of the electric car market, thanks to an impressive product portfolio and a rapidly developing Supercharger network